BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383-403. [PMID: 29599078 DOI: 10.1016/s2468-1253(18)30056-6] [Cited by in Crossref: 511] [Cited by in F6Publishing: 269] [Article Influence: 170.3] [Reference Citation Analysis]
Number Citing Articles
1 Xiao C, Mei F, Ren G, Long L, Chen M, Fang X, Li J, Li K, Tang Y, Huang T, Deng W. Synergistic Effect of MC-LR and C-Terminal Truncated HBx on HepG2 Cells and Their Effects on PP2A Mediated Downstream Target of MAPK Signaling Pathway. Front Genet 2020;11:537785. [PMID: 33193609 DOI: 10.3389/fgene.2020.537785] [Reference Citation Analysis]
2 Li C, Zhang W, Shi B, Chen G, Zheng Y, An Y, Sun M, Feng Y, Shang Q, Zhang X. Evaluation of the in situ assay for HBV DNA: An observational real-world study in chronic hepatitis B. Medicine (Baltimore) 2021;100:e27220. [PMID: 34664859 DOI: 10.1097/MD.0000000000027220] [Reference Citation Analysis]
3 Hu J, Wang Y, Jiang G, Zheng J, Chen T, Chen Z, Yang M, Zhang X, Zhao H, Li L. Predictors of inflammatory activity in treatment-naive hepatitis B e-antigen-negative patients with chronic hepatitis B infection. J Int Med Res 2020;48:300060520969582. [PMID: 33179557 DOI: 10.1177/0300060520969582] [Reference Citation Analysis]
4 Schlicksup CJ, Laughlin P, Dunkelbarger S, Wang JC, Zlotnick A. Local Stabilization of Subunit-Subunit Contacts Causes Global Destabilization of Hepatitis B Virus Capsids. ACS Chem Biol 2020;15:1708-17. [PMID: 32369333 DOI: 10.1021/acschembio.0c00320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
5 Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2019;3:8-19. [PMID: 30619990 DOI: 10.1002/hep4.1281] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
6 Hosking K, Stewart G, Mobsby M, Skov S, Zhao Y, Su JY, Tong S, Nihill P, Davis J, Connors C, Davies J. Data linkage and computerised algorithmic coding to enhance individual clinical care for Aboriginal people living with chronic hepatitis B in the Northern Territory of Australia - Is it feasible? PLoS One 2020;15:e0232207. [PMID: 32343712 DOI: 10.1371/journal.pone.0232207] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kang SH, Cho DH, Choi J, Baik SK, Gwon JG, Kim MY. Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study. PLoS One 2021;16:e0258229. [PMID: 34610052 DOI: 10.1371/journal.pone.0258229] [Reference Citation Analysis]
8 Tavoschi L, Mason L, Petriti U, Bunge E, Veldhuijzen I, Duffell E. Hepatitis B and C among healthcare workers and patient groups at increased risk of iatrogenic transmission in the European Union/European Economic Area. J Hosp Infect 2019;102:359-68. [PMID: 30885816 DOI: 10.1016/j.jhin.2019.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Opara I, Lardier DT, Herrera A, Garcia-Reid P, Reid RJ. Increasing Viral Hepatitis Knowledge Among Urban Ethnic Minority Youth: Findings from a Community Based Prevention Intervention. J Community Health 2020;45:269-77. [PMID: 31515664 DOI: 10.1007/s10900-019-00740-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Xu Z, Zhao J, Liu J, Dong Y, Wang F, Yan J, Cao L, Wang P, Li A, Li J, Zhu S, Zhong Y, Zhang M, Wang FS. Assessment of liver fibrosis by transient elastography in young children with chronic hepatitis B virus infection. Hepatol Int 2021;15:602-10. [PMID: 34240319 DOI: 10.1007/s12072-021-10194-7] [Reference Citation Analysis]
11 Suoh M, Tamori A, Amano-Teranishi Y, Nakai T, Enomoto M, Kawasaki Y, Kioka K, Kawada N. The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B. Intern Med 2020;59:205-10. [PMID: 31941870 DOI: 10.2169/internalmedicine.3504-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review. Euro Surveill 2019;24. [PMID: 31362808 DOI: 10.2807/1560-7917.ES.2019.24.30.1800614] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
13 Edwards TC, Ponzar NL, Tavis JE. Shedding light on RNaseH: a promising target for hepatitis B virus (HBV). Expert Opin Ther Targets 2019;23:559-63. [PMID: 31084514 DOI: 10.1080/14728222.2019.1619697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Maravelia P, Frelin L, Ni Y, Caro Pérez N, Ahlén G, Jagya N, Verch G, Verhoye L, Pater L, Johansson M, Pasetto A, Meuleman P, Urban S, Sällberg M. Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections. J Infect Dis 2021;223:128-38. [PMID: 31994701 DOI: 10.1093/infdis/jiaa036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Megahed FAK, Zhou X, Sun P. The Interactions between HBV and the Innate Immunity of Hepatocytes. Viruses 2020;12:E285. [PMID: 32151000 DOI: 10.3390/v12030285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
16 Khan AF, Sajjad A, Mian DA, Tariq MM, Jadoon UK, Abbas M, Shakeel K, Saeed N, Abbas K. Co-infection With Hepatitis B in Tuberculosis Patients on Anti-tuberculosis Treatment and the Final Outcome. Cureus 2021;13:e14433. [PMID: 33996299 DOI: 10.7759/cureus.14433] [Reference Citation Analysis]
17 Yang F. Post-translational Modification Control of HBV Biological Processes. Front Microbiol 2018;9:2661. [PMID: 30443247 DOI: 10.3389/fmicb.2018.02661] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
18 Yoda T, Katsuyama H. Analysis of antibody-negative medical students after hepatitis B vaccination in Japan. Hum Vaccin Immunother 2021;17:852-6. [PMID: 32755433 DOI: 10.1080/21645515.2020.1788309] [Reference Citation Analysis]
19 Luo X, Zhang R, Lu M, Liu S, Baba HA, Gerken G, Wedemeyer H, Broering R. Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection. Front Immunol 2021;12:684424. [PMID: 34113355 DOI: 10.3389/fimmu.2021.684424] [Reference Citation Analysis]
20 Moore MS, Bocour A, Winters A. Surveillance-Based Estimate of the Prevalence of Chronic Hepatitis B Virus Infection, New York City, 2016. Public Health Rep 2019;134:695-702. [PMID: 31647883 DOI: 10.1177/0033354919882962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Wang J, Liu R, Zhao Y, Ma Z, Sang Z, Wen Z, Yang X, Xie H. Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging. Front Oncol 2021;11:743055. [PMID: 34513717 DOI: 10.3389/fonc.2021.743055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Johannessen A, Mekasha B, Desalegn H, Aberra H, Stene-Johansen K, Berhe N. Mother-to-Child Transmission of Hepatitis B Virus in Ethiopia. Vaccines (Basel) 2021;9:430. [PMID: 33925930 DOI: 10.3390/vaccines9050430] [Reference Citation Analysis]
23 Van Haele M, Snoeck J, Roskams T. Human Liver Regeneration: An Etiology Dependent Process. Int J Mol Sci 2019;20:E2332. [PMID: 31083462 DOI: 10.3390/ijms20092332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
24 Khetsuriani N, Mosina L, Van Damme P, Mozalevskis A, Datta S, Tohme RA. Progress Toward Hepatitis B Control - World Health Organization European Region, 2016-2019. MMWR Morb Mortal Wkly Rep 2021;70:1029-35. [PMID: 34324482 DOI: 10.15585/mmwr.mm7030a1] [Reference Citation Analysis]
25 Hong J, Choi Y, Choi Y, Lee J, Hong HJ. Epitope-Paratope Interaction of a Neutralizing Human Anti-Hepatitis B Virus PreS1 Antibody That Recognizes the Receptor-Binding Motif. Vaccines (Basel) 2021;9:754. [PMID: 34358170 DOI: 10.3390/vaccines9070754] [Reference Citation Analysis]
26 Udomkarnjananun S, Takkavatakarn K, Praditpornsilpa K, Nader C, Eiam-ong S, Jaber BL, Susantitaphong P. Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis. J Nephrol 2020;33:343-54. [DOI: 10.1007/s40620-019-00668-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
27 Sun H, Feng F, Xie H, Li X, Jiang Q, Chai Y, Wang Z, Yang R, Li R, Hou J. Quantitative examination of the inhibitory activation of molecular targeting agents in hepatocellular carcinoma patient-derived cell invasion via a novel in vivo tumor model. Animal Model Exp Med 2019;2:259-68. [PMID: 31942558 DOI: 10.1002/ame2.12085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
28 Lee AU, Mair L, Kevin B, Gandi L, Tarumuri O, Lee C, Huntley S, Hilmers DC. Prevalence of chronic hepatitis B in Oro Province, Papua New Guinea. Western Pac Surveill Response J 2020;11:6-9. [PMID: 34046236 DOI: 10.5365/wpsar.2020.11.3.001] [Reference Citation Analysis]
29 Bollinger RC, Thio CL, Sulkowski MS, McKenzie-White J, Thomas DL, Flexner C. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. Lancet HIV 2020;7:e443-8. [PMID: 31870675 DOI: 10.1016/S2352-3018(19)30342-X] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
30 Charlton MR, Alam A, Shukla A, Dashtseren B, Lesmana CRA, Duger D, Payawal DA, Duy Cuong D, Jargalsaikhan G, Cua IHY, Sollano JD, Singh KR, Madan K, Win KM, Kyi KP, Tun KS, Salih M, Rastogi M, Saraf N, Thuy PTT, Hien PTD, Gani RA, Mohamed R, Tanwandee T, Piratvisuth T, Sukeepaisarnjaroen W, Naing W, Hashmi ZY. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol 2020;55:811-23. [PMID: 32666200 DOI: 10.1007/s00535-020-01698-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
31 Ju YC, Jun DW, Yoon EL, Ahn SB, Kim YJ, Nguyen MH. Nationwide Data on the Characteristics of Linked-to-Care Chronic Hepatitis B in Korea. J Clin Med 2021;10:4633. [PMID: 34682760 DOI: 10.3390/jcm10204633] [Reference Citation Analysis]
32 Liang LY, Lee HW, Wong VW, Yip TC, Tse YK, Hui VW, Lui GC, Chan HL, Wong GL. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:499-509. [PMID: 33631920 DOI: 10.3350/cmh.2020.0333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Seerat I, Mushtaq H, Rafiq M, Nadir A. Frequency and Associated Risk Factors of Hepatitis B Virus and Hepatitis C Virus Infections in Children at a Hepatitis Prevention and Treatment Clinic in Lahore, Pakistan. Cureus 2020;12:e7926. [PMID: 32494536 DOI: 10.7759/cureus.7926] [Reference Citation Analysis]
34 Zhang YL, Gao Y, Cao JL, Zhao JH, Zhang TY, Yang CL, Xiong HL, Wang YB, Ou SH, Cheng T, Chen CR, Yuan Q, Xia NS. Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. Emerg Microbes Infect 2019;8:724-33. [PMID: 31130075 DOI: 10.1080/22221751.2019.1619485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Pley CM, McNaughton AL, Matthews PC, Lourenço J. The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. BMJ Glob Health 2021;6:e004275. [PMID: 33402334 DOI: 10.1136/bmjgh-2020-004275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
36 Yu Y, Guo D, Qu T, Zhao S, Xu C, Wang L, Wang Z, Fu H, Zhang X, Zhou N. Increased Risk of Toxoplasma gondii Infection in Patients with Colorectal Cancer in Eastern China: Seroprevalence, Risk Factors, and a Case-Control Study. Biomed Res Int 2020;2020:2539482. [PMID: 33083457 DOI: 10.1155/2020/2539482] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ogawa E, Yeo YH, Dang N, Le MH, Jeong D, Tran S, Henry L, Cheung R, Nguyen MH. Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. JAMA Netw Open 2020;3:e201844. [PMID: 32271388 DOI: 10.1001/jamanetworkopen.2020.1844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
38 Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, Omata M, Ooka Y, Han KH, Lee HW, Jafri W, Butt AS, Chong CH, Lim SG, Pwu RF, Chen DS. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5:167-228. [PMID: 31852635 DOI: 10.1016/s2468-1253(19)30342-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 34] [Article Influence: 29.0] [Reference Citation Analysis]
39 Drake TM, Knight SR, Harrison EM, Søreide K. Global Inequities in Precision Medicine and Molecular Cancer Research. Front Oncol 2018;8:346. [PMID: 30234014 DOI: 10.3389/fonc.2018.00346] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
40 Muraleedharan A, Bupesh G. A short note on HBV infection. Bioinformation 2020;16:505-8. [PMID: 32994674 DOI: 10.6026/97320630016505] [Reference Citation Analysis]
41 Coste M, De Sèze M, Diallo A, Carrieri MP, Marcellin F, Boyer S; ANRS 12356 AmBASS Study Group. Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). BMJ Open 2019;9:e030211. [PMID: 31320358 DOI: 10.1136/bmjopen-2019-030211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
42 Guimarães LCDC, Brunini S, Guimarães RA, Galdino-Júnior H, Minamisava R, da Cunha VE, Santos JRS, Silveira-Lacerda EP, Souza CM, de Oliveira VLB, Albernaz GC, de Menezes TG, Rezza G. Epidemiology of hepatitis B virus infection in people living in poverty in the central-west region of Brazil. BMC Public Health 2019;19:443. [PMID: 31035990 DOI: 10.1186/s12889-019-6828-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Ma X, McKeen T, Zhang J, Ding WX. Role and Mechanisms of Mitophagy in Liver Diseases. Cells 2020;9:E837. [PMID: 32244304 DOI: 10.3390/cells9040837] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
44 Yang J, He X, Lv Q, Jing J, Shi H. Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Front Pharmacol 2019;10:726. [PMID: 31312140 DOI: 10.3389/fphar.2019.00726] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
45 Van Damme P, Dionne M, Leroux-Roels G, Van Der Meeren O, Di Paolo E, Salaun B, Surya Kiran P, Folschweiller N. Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults. J Viral Hepat. 2019;26:1066-1075. [PMID: 31087382 DOI: 10.1111/jvh.13125] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
46 Freeland C, Bodor S, Perera U, Cohen C. Barriers to Hepatitis B Screening and Prevention for African Immigrant Populations in the United States: A Qualitative Study. Viruses 2020;12:E305. [PMID: 32168926 DOI: 10.3390/v12030305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
47 Pérez-Segura C, Goh BC, Hadden-Perilla JA. All-Atom MD Simulations of the HBV Capsid Complexed with AT130 Reveal Secondary and Tertiary Structural Changes and Mechanisms of Allostery. Viruses 2021;13:564. [PMID: 33810481 DOI: 10.3390/v13040564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kadelka S, Dahari H, Ciupe SM. Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection. Sci Rep 2021;11:200. [PMID: 33420293 DOI: 10.1038/s41598-020-80594-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
49 Lin Y, Zhao Z, Huang A, Lu M. Interplay between Cellular Autophagy and Hepatitis B Virus Replication: A Systematic Review. Cells 2020;9:E2101. [PMID: 32942717 DOI: 10.3390/cells9092101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol. 2019;5:30-36. [PMID: 30267080 DOI: 10.1001/jamaoncol.2018.4070] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 54.0] [Reference Citation Analysis]
51 Lai FTT, Beeler PE, Yip BHK, Cheetham M, Chau PYK, Chung RY, Wong ELY, Yeoh EK, Battegay E, Wong SYS. Comparing Multimorbidity Patterns Among Discharged Middle-Aged and Older Inpatients Between Hong Kong and Zurich: A Hierarchical Agglomerative Clustering Analysis of Routine Hospital Records. Front Med (Lausanne) 2021;8:651925. [PMID: 34368178 DOI: 10.3389/fmed.2021.651925] [Reference Citation Analysis]
52 Zheng Y, Zhang L, Zhu X, Guo G. A comparative study of two methods to predict the incidence of hepatitis B in Guangxi, China.PLoS One. 2020;15:e0234660. [PMID: 32579598 DOI: 10.1371/journal.pone.0234660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Nyarko E, Obirikorang C, Owiredu WKBA, Adu EA, Acheampong E, Aidoo F, Ofori E, Addy BS, Asare-Anane H. NTCP gene polymorphisms and hepatitis B virus infection status in a Ghanaian population. Virol J 2020;17:91. [PMID: 32620148 DOI: 10.1186/s12985-020-01376-0] [Reference Citation Analysis]
54 Viswanathan U, Mani N, Hu Z, Ban H, Du Y, Hu J, Chang J, Guo JT. Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B. Antiviral Res 2020;182:104917. [PMID: 32818519 DOI: 10.1016/j.antiviral.2020.104917] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
55 Lechner S, Yee M, Limketkai BN, Pham EA. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Dig Dis Sci 2020;65:897-905. [PMID: 32020359 DOI: 10.1007/s10620-020-06100-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
56 Peng W, Li JW, Zhang XY, Li C, Wen TF, Yan LN, Yang JY. A novel model for predicting posthepatectomy liver failure in patients with hepatocellular carcinoma. PLoS One 2019;14:e0219219. [PMID: 31269063 DOI: 10.1371/journal.pone.0219219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
57 Jiang Q, Ma Y, Han J, Chu J, Ma X, Shen L, Liu B, Li BA, Hou J, Bi Q. MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor. Front Oncol 2021;11:715193. [PMID: 34249768 DOI: 10.3389/fonc.2021.715193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Yang L, Wang Q, Cui T, Huang J, Jin H. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:9996358. [PMID: 34513751 DOI: 10.1155/2021/9996358] [Reference Citation Analysis]
59 Mokaya J, Burn EAO, Tamandjou CR, Goedhals D, Barnes EJ, Andersson M, Pinedo-Villanueva R, Matthews PC. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health 2019;19:829. [PMID: 31242901 DOI: 10.1186/s12889-019-7095-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
60 Huang DQ, Yeo YH, Tan E, Takahashi H, Yasuda S, Saruwatari J, Tanaka K, Oniki K, Kam LY, Muthiah MD, Hyogo H, Ono M, Barnett SD, Li J, Zou B, Fung J, Lee TY, Wong VW, Yuen MF, Dan YY, Lim SG, Cheung R, Toyoda H, Eguchi Y, Nguyen MH. ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. Hepatol Commun 2020;4:1624-36. [PMID: 33163833 DOI: 10.1002/hep4.1593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
61 Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, Bulterys M. Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67:773-777. [PMID: 30025413 DOI: 10.15585/mmwr.mm6728a2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 13.7] [Reference Citation Analysis]
62 Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World J Gastroenterol 2018; 24(31): 3488-3499 [PMID: 30131655 DOI: 10.3748/wjg.v24.i31.3488] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
63 Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ 2019;97:230-8. [PMID: 30992636 DOI: 10.2471/BLT.18.219469] [Cited by in Crossref: 57] [Cited by in F6Publishing: 29] [Article Influence: 28.5] [Reference Citation Analysis]
64 Mentha N, Clément S, Negro F, Alfaiate D. A review on hepatitis D: From virology to new therapies. J Adv Res 2019;17:3-15. [PMID: 31193285 DOI: 10.1016/j.jare.2019.03.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 18.0] [Reference Citation Analysis]
65 Liu R, Guo J, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Li M, Xie Y. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clin Exp Med 2019;19:309-20. [PMID: 31111345 DOI: 10.1007/s10238-019-00560-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
66 Mohd-Ismail NK, Lim Z, Gunaratne J, Tan YJ. Mapping the Interactions of HBV cccDNA with Host Factors. Int J Mol Sci. 2019;20. [PMID: 31480501 DOI: 10.3390/ijms20174276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
67 Coffin CS, Zhou K, Terrault NA. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology 2019;156:355-368.e3. [PMID: 30472225 DOI: 10.1053/j.gastro.2018.11.037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
68 Tsounis EP, Mouzaki A, Triantos C. Nucleic acid vaccines: A taboo broken and prospect for a hepatitis B virus cure. World J Gastroenterol 2021; 27(41): 7005-7013 [DOI: 10.3748/wjg.v27.i41.7005] [Reference Citation Analysis]
69 Lee AU, Jackson K, Tekoaua R, Lee C, Huntley MS, Hilmers DC. A programme to treat chronic hepatitis B in Kiribati: progress and challenges. Western Pac Surveill Response J 2020;11:21-5. [PMID: 33936856 DOI: 10.5365/wpsar.2019.10.4.003] [Reference Citation Analysis]
70 Pettersson JH, Myking S, Elshaug H, Bygdås KIE, Stene-Johansen K. Molecular epidemiology of hepatitis B virus infection in Norway. BMC Infect Dis 2019;19:236. [PMID: 30845915 DOI: 10.1186/s12879-019-3868-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
71 Toor J, Echeverria-Londono S, Li X, Abbas K, Carter ED, Clapham HE, Clark A, de Villiers MJ, Eilertson K, Ferrari M, Gamkrelidze I, Hallett TB, Hinsley WR, Hogan D, Huber JH, Jackson ML, Jean K, Jit M, Karachaliou A, Klepac P, Kraay A, Lessler J, Li X, Lopman BA, Mengistu T, Metcalf CJE, Moore SM, Nayagam S, Papadopoulos T, Perkins TA, Portnoy A, Razavi H, Razavi-Shearer D, Resch S, Sanderson C, Sweet S, Tam Y, Tanvir H, Tran Minh Q, Trotter CL, Truelove SA, Vynnycky E, Walker N, Winter A, Woodruff K, Ferguson NM, Gaythorpe KA. Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. Elife 2021;10:e67635. [PMID: 34253291 DOI: 10.7554/eLife.67635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Yin XR, Liu ZH, Liu J, Liu YY, Xie L, Tao LB, Jia JD, Cui FQ, Zhuang GH, Hou JL. First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China. Chin Med J (Engl) 2019;132:2315-24. [PMID: 31567376 DOI: 10.1097/CM9.0000000000000445] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Hyun S, Ko O, Kim S, Ventura WR. Sociocultural barriers to hepatitis B health literacy in an immigrant population: a focus group study in Korean Americans. BMC Public Health 2021;21:404. [PMID: 33632203 DOI: 10.1186/s12889-021-10441-4] [Reference Citation Analysis]
74 Kumar P, Freeland C, Bodor S, Farrell S, Cohen C, Frasso R. Needs of Individuals Living With Hepatitis Delta Virus and Their Caregivers, 2016-2019. Prev Chronic Dis 2020;17:E159. [PMID: 33337297 DOI: 10.5888/pcd17.200324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Wang L, Wu L, Li X, Zhang Y, Lai J, Zhu X, Xie C, Peng L. Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial. BMJ Open 2021;11:e048410. [PMID: 34408049 DOI: 10.1136/bmjopen-2020-048410] [Reference Citation Analysis]
76 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588-4603. [PMID: 30091725 DOI: 10.1172/jci121960] [Cited by in Crossref: 103] [Cited by in F6Publishing: 62] [Article Influence: 34.3] [Reference Citation Analysis]
78 Sharafi H, Alavian SM. The Rising Threat of Hepatocellular Carcinoma in the Middle East and North Africa Region: Results From Global Burden of Disease Study 2017. Clin Liver Dis (Hoboken) 2019;14:219-23. [PMID: 32015873 DOI: 10.1002/cld.890] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
79 Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol 2021; 27(36): 6025-6038 [PMID: 34629817 DOI: 10.3748/wjg.v27.i36.6025] [Reference Citation Analysis]
80 Wang S, Tao Y, Tao Y, Jiang J, Yan L, Wang C, Ding Y, Yu J, Zhao D, Chi X, Wang X, Wu R, Gao X, Shi Y, Guan Y, Li Y, Xing Y, Sun H, Ta C, Wang C, Niu J, Meng J, Xu H. Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study. BMC Public Health 2018;18:1088. [PMID: 30176842 DOI: 10.1186/s12889-018-5984-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
81 Halatoko WA, Patassi A, Yanogo P, Banla LI, Koba A, Issa Z, Akolly K, Tchalla AM, Assane H, Naba-Mouchedou A, Sawadogo B, Antara SN, Badziklou K, Banla AK, Ekouevi DK, Sanou I. Risk factors of hepatitis B virus surface antigen carriage and serological profile of HBsAg carriers in Lomé Togo, 2016. BMC Public Health 2019;19:32. [PMID: 30621652 DOI: 10.1186/s12889-018-6320-x] [Reference Citation Analysis]
82 Zhou JY, Song LW, Yuan R, Lu XP, Wang GQ. Prediction of hepatic inflammation in chronic hepatitis B patients with a random forest-backward feature elimination algorithm. World J Gastroenterol 2021; 27(21): 2910-2920 [PMID: 34135561 DOI: 10.3748/wjg.v27.i21.2910] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Lai Q, Mennini G, Giovanardi F, Rossi M, Giannini EG. Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A meta-analysis. Eur J Clin Invest 2021;51:e13575. [PMID: 33866547 DOI: 10.1111/eci.13575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Xie H, Tian S, Cui L, Yan J, Bai Y, Li X, Wang M, Zhang F, Duan F. Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma. Cancer Manag Res 2019;11:4065-73. [PMID: 31118814 DOI: 10.2147/CMAR.S195485] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
85 Drazilova S, Janicko M, Kristian P, Schreter I, Halanova M, Urbancikova I, Madarasova-Geckova A, Marekova M, Pella D, Jarcuska P; HepaMeta Team. Prevalence and Risk Factors for Hepatitis B Virus Infection in Roma and Non-Roma People in Slovakia. Int J Environ Res Public Health. 2018;15:1047. [PMID: 29789486 DOI: 10.3390/ijerph15051047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
86 Kim GA, Shim JJ, Lee JS, Kim BH, Kim JW, Oh CH, Oh CM, Oh IH, Park SY. Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B. Yonsei Med J 2019;60:1203-8. [PMID: 31769252 DOI: 10.3349/ymj.2019.60.12.1203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 37.0] [Reference Citation Analysis]
88 Olakunde BO, Adeyinka DA, Olakunde OA, Uthman OA, Bada FO, Nartey YA, Obiri-Yeboah D, Paintsil E, Ezeanolue EE. A systematic review and meta-analysis of the prevalence of hepatitis B virus infection among pregnant women in Nigeria. PLoS One 2021;16:e0259218. [PMID: 34714888 DOI: 10.1371/journal.pone.0259218] [Reference Citation Analysis]
89 Mrzljak A, Bajkovec L, Vilibic-Cavlek T. Hepatotropic viruses: Is Roma population at risk? World J Gastroenterol 2021; 27(2): 143-151 [PMID: 33510555 DOI: 10.3748/wjg.v27.i2.143] [Reference Citation Analysis]
90 Sun T, Li R, Qiu Y, Shen S, Wang W. New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram. Int J Gen Med 2021;14:6149-65. [PMID: 34611429 DOI: 10.2147/IJGM.S335400] [Reference Citation Analysis]
91 Hanson J, Fox M, Anderson A, Fox P, Webster K, Williams C, Nield B, Bagshaw R, Hempenstall A, Smith S, Solomon N, Boyd P. Chronic hepatitis B in remote, tropical Australia; successes and challenges. PLoS One 2020;15:e0238719. [PMID: 32881958 DOI: 10.1371/journal.pone.0238719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
92 Mak LY, Wong DK, Cheung KS, Seto WK, Fung J, Yuen MF. First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. BMC Gastroenterol 2021;21:123. [PMID: 33731023 DOI: 10.1186/s12876-021-01711-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Xu H, Li X, Wu Z, Zhao L, Shen J, Liu J, Qin J, Shen Y, Ke J, Wei Y, Li J, Gao Y. LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB. Front Mol Biosci 2021;8:749648. [PMID: 34631799 DOI: 10.3389/fmolb.2021.749648] [Reference Citation Analysis]
94 Li Q, Lomonosova E, Donlin MJ, Cao F, O'Dea A, Milleson B, Berkowitz AJ, Baucom JC, Stasiak JP, Schiavone DV, Abdelmessih RG, Lyubimova A, Fraboni AJ, Bejcek LP, Villa JA, Gallicchio E, Murelli RP, Tavis JE. Amide-containing α-hydroxytropolones as inhibitors of hepatitis B virus replication. Antiviral Res 2020;177:104777. [PMID: 32217151 DOI: 10.1016/j.antiviral.2020.104777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
95 Pierra Rouviere C, Dousson CB, Tavis JE. HBV replication inhibitors. Antiviral Res 2020;179:104815. [PMID: 32380149 DOI: 10.1016/j.antiviral.2020.104815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
96 Chao SH, Chang YL, Yen JC, Liao HT, Wu TH, Yu CL, Tsai CY, Chou YC. Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis. Exp Hematol Oncol 2020;9:6. [PMID: 32322437 DOI: 10.1186/s40164-020-00163-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Yang Y, Song L, Cao J, Liu J, Wang D, Wong LL, Zhao L. Active Chronic Hepatitis B increases the risk of Colorectal Liver Metastasis - A retrospective cross-sectional study. J Cancer 2021;12:1398-405. [PMID: 33531985 DOI: 10.7150/jca.51233] [Reference Citation Analysis]
98 Tu T, Zhang H, Urban S. Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence. Viruses 2021;13:180. [PMID: 33530322 DOI: 10.3390/v13020180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Abutaleb A, Khatun M, Clement J, Baidya A, Singh P, Datta S, Ahammed SM, George K, Mukherjee P, Santra A, Neogi S, Parikh S, Pillai V, Kottilil S, Chowdhury A. A Model of Care Optimized for Marginalized Remote Population Unravels Migration Pattern in India. Hepatology 2021;73:1261-74. [PMID: 32659859 DOI: 10.1002/hep.31461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019;12:1629-40. [PMID: 30881018 DOI: 10.2147/OTT.S196713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
101 Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J 2019;10:365-81. [PMID: 31832112 DOI: 10.1007/s13167-019-00194-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 28.5] [Reference Citation Analysis]
102 Li G, Lin J, Jiang C, Feng Q, Wen L. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis. J Int Med Res 2020;48:300060519893234. [PMID: 31878813 DOI: 10.1177/0300060519893234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Berke JM, Dehertogh P, Vergauwen K, Mostmans W, Vandyck K, Raboisson P, Pauwels F. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379. Antimicrob Agents Chemother. 2020;64:e02439-19. [PMID: 32094138 DOI: 10.1128/aac.02439-19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
104 Liu Y, Ren J, Wu Z, Shen L, Shan H, Dai X, Li J, Qiu Y, Ren W, Yao J, Li L. The effect of hepatitis B vaccination after five years on an entire population in an insular region of Southeast China. Hum Vaccin Immunother 2021;17:1530-5. [PMID: 33315518 DOI: 10.1080/21645515.2020.1814096] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
106 Koc ÖM, Robaeys G, Yildirim B, Posthouwer D, Hens N, Koek GH. The influence of ethnicity on disease outcome in patients with chronic hepatitis B infection. J Med Virol 2019;91:623-9. [PMID: 30381836 DOI: 10.1002/jmv.25353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
107 Al-Busafi SA, Al-Harthi R, Al-Naamani K, Al-Zuhaibi H, Priest P. Risk Factors for Hepatitis B Virus Transmission 
in Oman. Oman Med J 2021;36:e287. [PMID: 34405055 DOI: 10.5001/omj.2021.99] [Reference Citation Analysis]
108 Schmit N, Nayagam S, Thursz MR, Hallett TB. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. Int J Epidemiol. 2021;50:560-569. [PMID: 33367672 DOI: 10.1093/ije/dyaa253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Tu T, Zehnder B, Qu B, Urban S. D e novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA. JHEP Rep. 2021;3:100195. [PMID: 33385130 DOI: 10.1016/j.jhepr.2020.100195] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
110 Bielen R, Koc ÖM, Busschots D, Robaeys G, Aertgeerts B, Vaes B, Mamouris P, Mathei C, Goderis G, Nevens F. Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study. BMJ Open 2019;9:e026464. [PMID: 31072855 DOI: 10.1136/bmjopen-2018-026464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Hui VW, Chan SL, Wong VW, Liang LY, Yip TC, Lai JC, Yuen BW, Luk HW, Tse YK, Lee HW, Chan HL, Wong GL. Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. JHEP Rep 2020;2:100152. [PMID: 33024950 DOI: 10.1016/j.jhepr.2020.100152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
112 Xu SH, Wu F, Guo LH, Zhang WB, Xu HX. Liver fibrosis index-based nomograms for identifying esophageal varices in patients with chronic hepatitis B related cirrhosis. World J Gastroenterol 2020; 26(45): 7204-7221 [PMID: 33362377 DOI: 10.3748/wjg.v26.i45.7204] [Reference Citation Analysis]
113 Huang BX, Liu Y, Fan ZP, Si LL, Chen RJ, Wang J, Luo D, Wang FS, Xu DP, Liu XG. Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations. World J Gastroenterol 2020; 26(35): 5314-5327 [PMID: 32994690 DOI: 10.3748/wjg.v26.i35.5314] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Mak LY, Seto WK, Fung J, Yuen MF. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int 2020;14:35-46. [PMID: 31745711 DOI: 10.1007/s12072-019-09998-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
115 Wang D, Fu B, Shen X, Guo C, Liu Y, Zhang J, Sun R, Ye Y, Li J, Tian Z, Wei H. Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy. Signal Transduct Target Ther 2021;6:376. [PMID: 34737296 DOI: 10.1038/s41392-021-00776-0] [Reference Citation Analysis]
116 Singal AG, Murphy CC. Hepatocellular Carcinoma: A Roadmap to Reduce Incidence and Future Burden. J Natl Cancer Inst 2019;111:527-8. [PMID: 30544135 DOI: 10.1093/jnci/djy184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
117 Bazinet M, Anderson M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Vaillant A. Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy. Hepatol Commun 2021;5:1873-87. [PMID: 34558823 DOI: 10.1002/hep4.1767] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Liu R, Chen Y, Guo J, Li M, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Zhang H, Xie Y. The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients. BMC Infect Dis 2020;20:590. [PMID: 32778058 DOI: 10.1186/s12879-020-05320-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
119 Hwang N, Sun L, Noe D, Lam PYS, Zhou T, Block TM, Du Y. Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation. ACS Med Chem Lett 2021;12:1130-6. [PMID: 34267883 DOI: 10.1021/acsmedchemlett.1c00228] [Reference Citation Analysis]
120 Shan S, Jia J. Prevention of Mother-to-Child Transmission of Hepatitis B Virus in the Western Pacific Region. Clin Liver Dis (Hoboken) 2021;18:18-21. [PMID: 34484699 DOI: 10.1002/cld.1096] [Reference Citation Analysis]
121 Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696. [PMID: 31475028 DOI: 10.3389/fgene.2019.00696] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
122 Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73:523-532. [PMID: 32335166 DOI: 10.1016/j.jhep.2020.04.008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 55.0] [Reference Citation Analysis]
123 Li J, Wu Z, Wang GQ, Zhao H. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients. Chin Med J (Engl) 2021;134:1160-7. [PMID: 33734135 DOI: 10.1097/CM9.0000000000001418] [Reference Citation Analysis]
124 Dionne-Odom J, Njei B, Tita ATN. Elimination of Vertical Transmission of Hepatitis B in Africa: A Review of Available Tools and New Opportunities. Clin Ther 2018;40:1255-67. [PMID: 29983265 DOI: 10.1016/j.clinthera.2018.05.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
125 Roca Suarez AA, Testoni B, Baumert TF, Lupberger J. Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease. Front Immunol 2020;11:624034. [PMID: 33613561 DOI: 10.3389/fimmu.2020.624034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Mak LY, Seto WK, Yuen MF. Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. Viruses 2021;13:1169. [PMID: 34207458 DOI: 10.3390/v13061169] [Reference Citation Analysis]
127 Cruz GP, Sargento C, Ventura MC, Oliveira J, Saraiva da Cunha J. Occult hepatitis B infection by a recombinant D/C virus in an immunosuppressed patient. IDCases 2020;19:e00671. [PMID: 32226761 DOI: 10.1016/j.idcr.2019.e00671] [Reference Citation Analysis]
128 Shen K, Yang NS, Huang W, Fitzpatrick TS, Tang W, Zhao Y, Wang Y, Li L, Tucker JD. A crowdsourced intervention to decrease hepatitis B stigma in men who have sex with men in China: A cohort study. J Viral Hepat 2020;27:135-42. [PMID: 31571341 DOI: 10.1111/jvh.13213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
129 Revill PA, Penicaud C, Brechot C, Zoulim F. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes (Basel) 2019;10:E260. [PMID: 30939846 DOI: 10.3390/genes10040260] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
130 Li M, Lv T, Wu S, Wei W, Wu X, Ou X, Ma H, Chow SC, Kong Y, You H, Jia J. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int. 2020;14:105-114. [PMID: 31898210 DOI: 10.1007/s12072-019-10005-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
131 Khue PM, Thuy Linh NT, Vinh VH, Dung LV, Nguyen Van B. Hepatitis B Infection and Mother-to-Child Transmission in Haiphong, Vietnam: A Cohort Study with Implications for Interventions. Biomed Res Int 2020;2020:4747965. [PMID: 32884940 DOI: 10.1155/2020/4747965] [Reference Citation Analysis]
132 Yin F, Feng F, Wang L, Wang X, Li Z, Cao Y. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. Cell Death Dis 2019;10:672. [PMID: 31511501 DOI: 10.1038/s41419-019-1884-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 15.0] [Reference Citation Analysis]
133 Zhang L, Wang Z. Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B. Virol J 2020;17:40. [PMID: 32188476 DOI: 10.1186/s12985-020-01314-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
134 Mansour-Ghanaei F, Joukar F, Naghipour M, Hassanipour S, Yeganeh S, Sepehrimanesh M, Fathalipour M. Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS). BMC Res Notes 2021;14:59. [PMID: 33568187 DOI: 10.1186/s13104-021-05474-2] [Reference Citation Analysis]
135 Zhao X, Shi X, Lv M, Yuan B, Wu J. Prevalence and factors associated with hepatitis B virus infection among household members: a cross-sectional study in Beijing. Hum Vaccin Immunother 2021;17:1818-24. [PMID: 33606606 DOI: 10.1080/21645515.2020.1847951] [Reference Citation Analysis]
136 Xiao Y, Wallace J, Ahad M, van Gemert C, Thompson AJ, Doyle J, Lam HY, Chan K, Bennett G, Adamson E, Yussf N, Tang A, Pedrana A, Stoove M, Hellard M, Howell J. Assessing the feasibility, acceptability and impacts of an education program on hepatitis B testing uptake among ethnic Chinese in Australia: results of a randomised controlled pilot study. BMC Public Health 2021;21:1861. [PMID: 34654385 DOI: 10.1186/s12889-021-11916-0] [Reference Citation Analysis]
137 Vieira Barbosa J, Sahli R, Aubert V, Chaouch A, Moradpour D, Fraga M. Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center. PLoS One 2021;16:e0250347. [PMID: 33905426 DOI: 10.1371/journal.pone.0250347] [Reference Citation Analysis]
138 Yuan J, Peng Y, Hao FB, Wang YQ, Wang CR, Zhong GC. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY) 2021;13:7147-65. [PMID: 33658397 DOI: 10.18632/aging.202573] [Reference Citation Analysis]
139 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, Susilo A, Tanaka Y, Chan WK, Gane E, Ong-Go AK, Lim SG, Ahn SH, Yu ML, Piratvisuth T, Chan HL;  Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020;5:776-787. [PMID: 32585136 DOI: 10.1016/s2468-1253(20)30190-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 27.0] [Reference Citation Analysis]
141 Khan M, Imam H, Siddiqui A. Subversion of cellular autophagy during virus infection: Insights from hepatitis B and hepatitis C viruses. Liver Res 2018;2:146-56. [PMID: 31803515 DOI: 10.1016/j.livres.2018.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
142 Tu T, Block JM, Wang S, Cohen C, Douglas MW. The Lived Experience of Chronic Hepatitis B: A Broader View of Its Impacts and Why We Need a Cure. Viruses 2020;12:E515. [PMID: 32392763 DOI: 10.3390/v12050515] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
143 Liu QM, He YY, Liu LL, Wang LK. Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection. J Inflamm Res 2021;14:5489-500. [PMID: 34720597 DOI: 10.2147/JIR.S315716] [Reference Citation Analysis]
144 Kitandwe PK, Muyanja E, Nakaweesa T, Nanvubya A, Ssetaala A, Mpendo J, Okech B, Bagaya BS, Kiwanuka N, Price MA. Hepatitis B prevalence and incidence in the fishing communities of Lake Victoria, Uganda: a retrospective cohort study. BMC Public Health 2021;21:394. [PMID: 33622281 DOI: 10.1186/s12889-021-10428-1] [Reference Citation Analysis]
145 Choi YM, Kim H, Lee SA, Lee SY, Kim BJ. A Telomerase-Derived Peptide Exerts an Anti-Hepatitis B Virus Effect via Mitochondrial DNA Stress-Dependent Type I Interferon Production. Front Immunol 2020;11:652. [PMID: 32508804 DOI: 10.3389/fimmu.2020.00652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
146 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021; 27(24): 3556-3567 [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Yip TC, Wong VW, Lui GC, Chow VC, Tse YK, Hui VW, Liang LY, Chan HL, Hui DS, Wong GL. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. Hepatology 2021. [PMID: 33961298 DOI: 10.1002/hep.31890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
148 Boye S, Shimakawa Y, Vray M, Giles-Vernick T. Limited Awareness of Hepatitis B but Widespread Recognition of Its Sequelae in Rural Senegal: A Qualitative Study. Am J Trop Med Hyg 2020;102:637-43. [PMID: 31971148 DOI: 10.4269/ajtmh.19-0477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
149 Miao N, Zheng H, Sun X, Shen L, Wang F, Cui F, Yin Z, Zhang G, Wang F. Enhanced sentinel surveillance for hepatitis B infection in 200 counties in China, 2013-2016. PLoS One 2019;14:e0215580. [PMID: 31013293 DOI: 10.1371/journal.pone.0215580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Nankya-Mutyoba J, Aizire J, Makumbi F, Atuyambe L, Ocama P, Kirk GD. Correlates of hepatitis B awareness and disease-specific knowledge among pregnant women in Northern and Central Uganda: a cross-sectional study. Hepatol Med Policy 2018;3:14. [PMID: 30598844 DOI: 10.1186/s41124-018-0043-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
151 Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Wang FS, Zhang L, Wu S, Tang H, Li J, Lin F, Yang Y, Gong G, Flaherty JF, Gaggar A, Mo S, Cheng C, Camus G, Chen C, Huang Y, Jia J, Zhang M; GS-US-320-0110 and GS-US-320-0108 China Investigators. 3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China. J Clin Transl Hepatol 2021;9:324-34. [PMID: 34221918 DOI: 10.14218/JCTH.2020.00145] [Reference Citation Analysis]
152 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Eneh PN, Mady M, Schmidt MA, Tilahun E, Hassan F, Njeru JW, Crane SJ, Chaudhry R, Roberts LR. Hepatitis B Screening of At-Risk Immigrants Seen at Primary Care Clinics: A Quality Improvement Project. Mayo Clin Proc Innov Qual Outcomes 2021;5:635-44. [PMID: 34195555 DOI: 10.1016/j.mayocpiqo.2021.04.002] [Reference Citation Analysis]
154 de Villiers MJ, Gamkrelidze I, Hallett TB, Nayagam S, Razavi H, Razavi-Shearer D. Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models. PLoS One 2020;15:e0237525. [PMID: 32776972 DOI: 10.1371/journal.pone.0237525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
155 Damrauer JS, Smith MA, Walter V, Thennavan A, Mose LE, Selitsky SR, Hoadley KA. Genomic characterization of rare molecular subclasses of hepatocellular carcinoma. Commun Biol 2021;4:1150. [PMID: 34608257 DOI: 10.1038/s42003-021-02674-1] [Reference Citation Analysis]
156 Wu YH, Yang Y, Chen CH, Hsiao CJ, Li TN, Liao KJ, Watashi K, Chen BS, Wang LH. Aerobic glycolysis supports hepatitis B virus protein synthesis through interaction between viral surface antigen and pyruvate kinase isoform M2. PLoS Pathog 2021;17:e1008866. [PMID: 33720996 DOI: 10.1371/journal.ppat.1008866] [Reference Citation Analysis]
157 Mokaya J, McNaughton AL, Burbridge L, Maponga T, O'Hara G, Andersson M, Seeley J, Matthews PC. A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review. Wellcome Open Res 2018;3:29. [PMID: 30483598 DOI: 10.12688/wellcomeopenres.14273.2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
158 Mancinelli R, Rosa L, Cutone A, Lepanto MS, Franchitto A, Onori P, Gaudio E, Valenti P. Viral Hepatitis and Iron Dysregulation: Molecular Pathways and the Role of Lactoferrin. Molecules 2020;25:E1997. [PMID: 32344579 DOI: 10.3390/molecules25081997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
159 McNaughton AL, Lourenço J, Bester PA, Mokaya J, Lumley SF, Obolski U, Forde D, Maponga TG, Katumba KR, Goedhals D, Gupta S, Seeley J, Newton R, Ocama P, Matthews PC. Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis. PLoS Med 2020;17:e1003068. [PMID: 32315297 DOI: 10.1371/journal.pmed.1003068] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
160 Yu XQ, Wang MJ, Yu DM, Chen PZ, Zhu MY, Huang W, Han Y, Gong QM, Zhang XX. Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients. J Clin Microbiol 2020;58:e00075-20. [PMID: 32554476 DOI: 10.1128/JCM.00075-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 McNaughton AL, Lourenço J, Hattingh L, Adland E, Daniels S, Van Zyl A, Akiror CS, Wareing S, Jeffery K, Ansari MA, Klenerman P, Goulder PJR, Gupta S, Jooste P, Matthews PC. HBV vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical cohort and dynamic model. BMC Med 2019;17:43. [PMID: 30786896 DOI: 10.1186/s12916-019-1269-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
162 Lam AM, Espiritu C, Vogel R, Ren S, Lau V, Kelly M, Kuduk SD, Hartman GD, Flores OA, Klumpp K. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus. Antimicrob Agents Chemother 2019;63:e01734-18. [PMID: 30373799 DOI: 10.1128/AAC.01734-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
163 Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res. 2020;180:104824. [PMID: 32450266 DOI: 10.1016/j.antiviral.2020.104824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 19.0] [Reference Citation Analysis]
164 Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Kim DJ. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. Clin Mol Hepatol 2020;26:209-15. [PMID: 31679316 DOI: 10.3350/cmh.2019.0065] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
165 Zhang TY, Guo XR, Wu YT, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Ge SX, Chen PJ, Zhang J, Yuan Q, Xia NS. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut 2020;69:343-54. [PMID: 30926653 DOI: 10.1136/gutjnl-2018-317725] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
166 Okoroiwu HU, Okafor IM, Asemota EA, Okpokam DC. Seroprevalence of transfusion-transmissible infections (HBV, HCV, syphilis and HIV) among prospective blood donors in a tertiary health care facility in Calabar, Nigeria; an eleven years evaluation. BMC Public Health 2018;18:645. [PMID: 29788937 DOI: 10.1186/s12889-018-5555-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
167 Brouard C, Saboni L, Gautier A, Chevaliez S, Rahib D, Richard JB, Barin F, Larsen C, Sommen C, Pillonel J, Delarocque-Astagneau E, Lydié N, Lot F; 2016 Health Barometer Group. HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy. BMC Infect Dis 2019;19:896. [PMID: 31660879 DOI: 10.1186/s12879-019-4493-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
168 Liu T, Li W, Zhang Y, Siyin ST, Zhang Q, Song M, Zhang K, Liu S, Shi H. Associations between hepatitis B virus infection and risk of colorectal Cancer: a population-based prospective study. BMC Cancer 2021;21:1119. [PMID: 34663268 DOI: 10.1186/s12885-021-08846-w] [Reference Citation Analysis]
169 Yang H, Mo J, Xiang Q, Zhao P, Song Y, Yang G, Wu K, Liu Y, Liu W, Wu J. SOX2 Represses Hepatitis B Virus Replication by Binding to the Viral EnhII/Cp and Inhibiting the Promoter Activation. Viruses 2020;12:E273. [PMID: 32121397 DOI: 10.3390/v12030273] [Reference Citation Analysis]
170 Li Y, Yin S, Chen Y, Zhang Q, Huang R, Jia B, Jie W, Yao K, Wang J, Tong X, Liu Y, Wu C. Hepatitis B virus-induced hyperactivation of B cells in chronic hepatitis B patients via TLR4. J Cell Mol Med 2020;24:6096-106. [PMID: 32391647 DOI: 10.1111/jcmm.15202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
171 Drazilova S, Kristian P, Janicko M, Halanova M, Safcak D, Dorcakova PD, Marekova M, Pella D, Madarasova-Geckova A, Jarcuska P, HepaMeta Team. What is the Role of the Horizontal Transmission of Hepatitis B Virus Infection in Young Adult and Middle-Aged Roma Population Living in the Settlements in East Slovakia? Int J Environ Res Public Health. 2020;17:3293. [PMID: 32397342 DOI: 10.3390/ijerph17093293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Li X, Liu X, Wang W. IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases. Front Cell Dev Biol 2021;9:614847. [PMID: 33777929 DOI: 10.3389/fcell.2021.614847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Smith-Palmer J, Cerri K, Sbarigia U, Chan EKH, Pollock RF, Valentine WJ, Bonroy K. Impact of Stigma on People Living with Chronic Hepatitis B. Patient Relat Outcome Meas 2020;11:95-107. [PMID: 32214859 DOI: 10.2147/PROM.S226936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
174 Orr C, Myers R, Li B, Jiang Z, Flaherty J, Gaggar A, Meissner EG. Longitudinal analysis of serum microRNAs as predictors of cirrhosis regression during treatment of hepatitis B virus infection. Liver Int 2020;40:1693-700. [PMID: 32301252 DOI: 10.1111/liv.14474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
175 Kim JU, Ingiliz P, Shimakawa Y, Lemoine M. Improving care of migrants is key for viral hepatitis elimination in Europe. Bull World Health Organ 2021;99:280-6. [PMID: 33953445 DOI: 10.2471/BLT.20.260919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Yu S, Yu C, Li J, Liu S, Wang H, Deng M. Hepatitis B and hepatitis C prevalence among people living with HIV/AIDS in China: a systematic review and Meta-analysis. Virol J 2020;17:127. [PMID: 32831118 DOI: 10.1186/s12985-020-01404-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
177 Yu Z, Deng M, Peng C, Song X, Chen Y, Zhang X, Liu Q, Li Y, Jiang H, Xu X, Pan L, Yuan J, Ruan B. A system dynamics modelling simulation based on a cohort of hepatitis B epidemic research in east China community. Epidemiol Infect 2019;147:e86. [PMID: 30821223 DOI: 10.1017/S0950268819000220] [Reference Citation Analysis]
178 Zhou X, Pan H, Yang P, Ye P, Cao H, Zhou H. Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma. BMC Cancer 2019;19:477. [PMID: 31113483 DOI: 10.1186/s12885-019-5718-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
179 Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, Zhang H, Kong H, Yang Y, Lu Y. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis 2019;10:784. [PMID: 31611551 DOI: 10.1038/s41419-019-2023-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
180 Zhao P, Lu Y, Wang C, Wang L, Li J, Li M. Clinical, Pathological and Genetic Characteristics of Pediatric Hepatocellular Carcinoma Associated with Hepatitis B Virus Infection. J Hepatocell Carcinoma 2021;8:361-7. [PMID: 34007834 DOI: 10.2147/JHC.S306963] [Reference Citation Analysis]
181 Gu S, Liu Z, Lin L, Zhong S, Ma Y, Li X, Ye G, Wen C, Li Y, Tang L. Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array. Front Immunol 2021;12:767000. [PMID: 34721439 DOI: 10.3389/fimmu.2021.767000] [Reference Citation Analysis]
182 Liang L, Huang DS, Yang T. Editorial: comorbidities in patients with chronic hepatitis B. Aliment Pharmacol Ther 2020;52:891-2. [PMID: 32852837 DOI: 10.1111/apt.15938] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Su SY. The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan. Hepatol Int 2019;13:157-64. [PMID: 30706354 DOI: 10.1007/s12072-019-09931-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 He X, Sun H, Jiang Q, Chai Y, Li X, Wang Z, Zhu B, You S, Li B, Hao J, Xin S. Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4. Front Oncol 2021;11:735447. [PMID: 34381736 DOI: 10.3389/fonc.2021.735447] [Reference Citation Analysis]
185 Mokaya J, McNaughton AL, Burbridge L, Maponga T, O'Hara G, Andersson M, Seeley J, Matthews PC. A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review. Wellcome Open Res 2018;3:29. [PMID: 30483598 DOI: 10.12688/wellcomeopenres.14273.2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
186 Qiao L, Tan W, Wang X, Zheng X, Huang Y, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Shang J, Liu J, Yan H, Gu W, Zhang Y, Xiang X, Hou Y, Zhang Q, Xiong Y, Zou C, Chen J, Huang Z, Jiang X, Luo S, Chen Y, Gao N, Liu C, Yuan W, Mei X, Li J, Li T, Zheng R, Zhou X, Chen J, Deng G, Zhang W, Li H. Different Effects of Total Bilirubin on 90-Day Mortality in Hospitalized Patients With Cirrhosis and Advanced Fibrosis: A Quantitative Analysis. Front Med (Lausanne) 2021;8:704452. [PMID: 34249983 DOI: 10.3389/fmed.2021.704452] [Reference Citation Analysis]
187 Ma Z, Zhang E, Gao S, Xiong Y, Lu M. Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response. Front Immunol 2019;10:2308. [PMID: 31608073 DOI: 10.3389/fimmu.2019.02308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
188 Han B, Liu W, Yang S, Wang S, Du J, Liu Y, Cui F. Association between self-monitoring of blood glucose and hepatitis B virus infection among people with diabetes mellitus: a cross-sectional study in Gansu Province, China. BMJ Open 2021;11:e048463. [PMID: 34620657 DOI: 10.1136/bmjopen-2020-048463] [Reference Citation Analysis]
189 Wang L, Cao X, Wang Z, Gao Y, Deng J, Liu X, Zhuang H. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients. J Clin Microbiol 2019;57:e01303-18. [PMID: 30355757 DOI: 10.1128/JCM.01303-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
190 Lu Y, Zeng J, Yang S, Hu Z, Li L, Yu H, Qin X. Association between the rs9131 and rs3806792 polymorphisms of the CXCL2 gene and the risk of HBV-related hepatocellular carcinoma in a Guangxi population. J Clin Lab Anal 2020;34:e23310. [PMID: 32267022 DOI: 10.1002/jcla.23310] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Ahmed S, Ayub M, Naeem M, Nazir FH, Hussain A, Ghilzai D, Magnius LO, Sajjad A, Norder H. Thalassemia Patients from Baluchistan in Pakistan Are Infected with Multiple Hepatitis B or C Virus Strains. Am J Trop Med Hyg 2021:tpmd200740. [PMID: 33534738 DOI: 10.4269/ajtmh.20-0740] [Reference Citation Analysis]
192 Tsounis EP, Tourkochristou E, Mouzaki A, Triantos C. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol 2021; 27(21): 2727-2757 [PMID: 34135551 DOI: 10.3748/wjg.v27.i21.2727] [Reference Citation Analysis]
193 Liu J, Hou Y, Sun L, Wang L, He Y, Zhou Y, Xu L, Liu X, Zhao F, Zhang L, Wang H, Wang FS. High population-attributable fractions of traditional risk factors for non-AIDS-defining diseases among people living with HIV in China: a cohort study. Emerg Microbes Infect 2021;10:416-23. [PMID: 33620297 DOI: 10.1080/22221751.2021.1894904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Shim JJ, Kim GA, Oh CH, Kim JW, Myung J, Kim BH, Oh IH. Reduced liver cancer mortality with regular clinic follow-up among patients with chronic hepatitis B: A nationwide cohort study. Cancer Med 2020;9:7781-91. [PMID: 32857923 DOI: 10.1002/cam4.3421] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Kang NL, Zhang JM, Lin MX, Chen XD, Huang ZX, Zhu YY, Liu YR, Zeng DW. Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World J Gastroenterol 2020; 26(27): 3952-3962 [PMID: 32774069 DOI: 10.3748/wjg.v26.i27.3952] [Reference Citation Analysis]
196 Ninomiya M, Inoue J, Krueger EW, Chen J, Cao H, Masamune A, McNiven MA. The Exosome-Associated Tetraspanin CD63 Contributes to the Efficient Assembly and Infectivity of the Hepatitis B Virus. Hepatol Commun 2021;5:1238-51. [PMID: 34278172 DOI: 10.1002/hep4.1709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
197 Nayagam S, Chan P, Zhao K, Sicuri E, Wang X, Jia J, Wei L, Walsh N, Rodewald LE, Zhang G, Ailing W, Zhang L, Chang JH, Hou W, Qiu Y, Sui B, Xiao Y, Zhuang H, Thursz MR, Scano F, Low-Beer D, Schwartländer B, Wang Y, Hallett TB. Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. Clin Infect Dis 2021;72:743-52. [PMID: 32255486 DOI: 10.1093/cid/ciaa134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
198 Fu B, Ji Y, Hu S, Ren T, Bhuva MS, Li G, Yang H. Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis. PLoS One 2020;15:e0227532. [PMID: 31940324 DOI: 10.1371/journal.pone.0227532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Pollicino T, Caminiti G. HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses 2021;13:368. [PMID: 33652619 DOI: 10.3390/v13030368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
200 Yao QY, Feng YD, Han P, Yang F, Song GQ. Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients. World J Gastroenterol 2020; 26(27): 3917-3928 [PMID: 32774066 DOI: 10.3748/wjg.v26.i27.3917] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Inoue J, Sato K, Ninomiya M, Masamune A. Envelope Proteins of Hepatitis B Virus: Molecular Biology and Involvement in Carcinogenesis. Viruses 2021;13:1124. [PMID: 34208172 DOI: 10.3390/v13061124] [Reference Citation Analysis]
202 Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 2018;7:F1000 Faculty Rev-921. [PMID: 30002817 DOI: 10.12688/f1000research.14841.1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
203 Athamneh RY, Arıkan A, Sayan M, Mahafzah A, Sallam M. Variable Proportions of Phylogenetic Clustering and Low Levels of Antiviral Drug Resistance among the Major HBV Sub-Genotypes in the Middle East and North Africa. Pathogens 2021;10:1333. [PMID: 34684283 DOI: 10.3390/pathogens10101333] [Reference Citation Analysis]
204 Nguyen TP, Luu HN, Nguyen MVT, Tran MT, Tuong TTV, Tran CTD, Boffetta P. Attributable Causes of Cancer in Vietnam. JCO Glob Oncol 2020;6:195-204. [PMID: 32045545 DOI: 10.1200/JGO.19.00239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
205 Moraras K, Block J, Shiroma N, Cannizzo A, Cohen C. Protecting the Rights of Health Care Students Living With Hepatitis B Under the Americans With Disabilities Act. Public Health Rep 2020;135:13S-8S. [PMID: 32735187 DOI: 10.1177/0033354920921252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
206 Lumley SF, McNaughton AL, Klenerman P, Lythgoe KA, Matthews PC. Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen. Front Immunol 2018;9:1561. [PMID: 30061882 DOI: 10.3389/fimmu.2018.01561] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
207 Hou FJ, Guo LX, Zheng KY, Song JN, Wang Q, Zheng YG. Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells. Onco Targets Ther 2019;12:6685-97. [PMID: 31695406 DOI: 10.2147/OTT.S215103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
208 Su M, Liao L, Xing H, Wang S, Li Y, Lu W, He L, Deng J, Shao Y, Li T, Zhuang H. Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China. Infect Drug Resist 2018;11:1635-44. [PMID: 30323633 DOI: 10.2147/IDR.S173757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
209 Chen L, Cao Z, Yan L, Ding Y, Shen X, Liu K, Xiang X, Xie Q, Zhu C, Bao S, Wang H. Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome. Front Physiol 2020;11:526. [PMID: 32655398 DOI: 10.3389/fphys.2020.00526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
210 van der Scheun FC, Nagelkerke MCM, Kilaru A, Shridhar V, Prasad R, van der Werf TS. Stigma among healthcare workers towards hepatitis B infection in Bangalore, India: a qualitative study. BMC Health Serv Res 2019;19:736. [PMID: 31640692 DOI: 10.1186/s12913-019-4606-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
211 Gosset A, Nishimwe ML, Diallo MY, Deroo L, Diallo A, Ba EH, Carrieri PM, Sokhna C, Vray M, Shimakawa Y, Boyer S. The Costs of Introducing the Hepatitis B Birth Dose Vaccine into the National Immunization Programme in Senegal (NéoVac Study). Vaccines (Basel) 2021;9:521. [PMID: 34070184 DOI: 10.3390/vaccines9050521] [Reference Citation Analysis]
212 Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R, Zoulim F; Members of the ICE-HBV Working Groups., ICE-HBV Stakeholders Group Chairs., ICE-HBV Senior Advisors. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 2019;4:545-58. [PMID: 30981686 DOI: 10.1016/S2468-1253(19)30119-0] [Cited by in Crossref: 141] [Cited by in F6Publishing: 91] [Article Influence: 70.5] [Reference Citation Analysis]
213 Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057 [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Reference Citation Analysis]
214 Meng Z, Chen Y, Lu M. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection. Front Immunol 2019;10:3127. [PMID: 32117201 DOI: 10.3389/fimmu.2019.03127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
215 Xia Y, Liang TJ. Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. Gastroenterology 2019;156:311-24. [PMID: 30243618 DOI: 10.1053/j.gastro.2018.07.057] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 14.7] [Reference Citation Analysis]
216 Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes (Basel) 2018;9:E483. [PMID: 30301171 DOI: 10.3390/genes9100483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
217 Dzingirai B, Katsidzira L, Matyanga CMJ, Postma MJ, van Hulst M, Mafirakureva N. Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges. J Viral Hepat 2021;28:994-1002. [PMID: 33797190 DOI: 10.1111/jvh.13510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Ji D, Chen Y, Shang Q, Liu H, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Hu X, Wang X, Chen D, Li Z, Dong Z, Chen G, Yang Y. Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B. Am J Gastroenterol 2021. [PMID: 33840727 DOI: 10.14309/ajg.0000000000001239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Waheed Y, Siddiq M, Jamil Z, Najmi MH. Hepatitis elimination by 2030: Progress and challenges. World J Gastroenterol 2018; 24(44): 4959-4961 [PMID: 30510370 DOI: 10.3748/wjg.v24.i44.4959] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
220 Stinco M, Rubino C, Trapani S, Indolfi G. Treatment of hepatitis B virus infection in children and adolescents. World J Gastroenterol 2021; 27(36): 6053-6063 [PMID: 34629819 DOI: 10.3748/wjg.v27.i36.6053] [Reference Citation Analysis]
221 Wang Y, Wang M, Zhang G, Ou X, Ma H, You H, Jia J. Control of Chronic Hepatitis B in China: Perspective of Diagnosis and Treatment. China CDC Wkly 2020;2:596-600. [PMID: 34594716 DOI: 10.46234/ccdcw2020.159] [Reference Citation Analysis]
222 Yang TW, Wang CC, Tsai MC, Wang YT, Tseng MH, Lin CC. Comorbidities and Outcome of Alcoholic and Non-Alcoholic Liver Cirrhosis in Taiwan: A Population-Based Study. Int J Environ Res Public Health 2020;17:E2825. [PMID: 32325957 DOI: 10.3390/ijerph17082825] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
223 Wang SH, Yeh SH, Chen PJ. Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. Cancers (Basel) 2021;13:2454. [PMID: 34070067 DOI: 10.3390/cancers13102454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
224 Veronese P, Dodi I, Esposito S, Indolfi G. Prevention of vertical transmission of hepatitis B virus infection. World J Gastroenterol 2021; 27(26): 4182-4193 [PMID: 34326618 DOI: 10.3748/wjg.v27.i26.4182] [Reference Citation Analysis]
225 Gu J, Yu G, Zhang X, Zhang S, Cai H, Ye C, Yang Y, Li D, Tong Z, Shen H, Chen H, Ding F, Lai X, Liu J, Xu M, Wu W. Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China. Virol J 2021;18:19. [PMID: 33441170 DOI: 10.1186/s12985-021-01491-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, Lou J, Wang Y, Liu N, Guo Q, Jia Y, Gao C. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China. J Clin Lab Anal 2021;35:e24013. [PMID: 34590755 DOI: 10.1002/jcla.24013] [Reference Citation Analysis]
227 Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. World J Gastroenterol 2021; 27(26): 3971-3983 [PMID: 34326608 DOI: 10.3748/wjg.v27.i26.3971] [Reference Citation Analysis]
228 Le C, Sirajee R, Steenbergen R, Joyce MA, Addison WR, Tyrrell DL. In Vitro Infection with Hepatitis B Virus Using Differentiated Human Serum Culture of Huh7.5-NTCP Cells without Requiring Dimethyl Sulfoxide. Viruses 2021;13:97. [PMID: 33445753 DOI: 10.3390/v13010097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
229 Singh P, Kairuz D, Arbuthnot P, Bloom K. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol 2021; 27(23): 3182-3207 [PMID: 34163105 DOI: 10.3748/wjg.v27.i23.3182] [Reference Citation Analysis]
230 Dunn R, Musabaev E, Razavi H, Sadirova S, Bakieva S, Razavi-Shearer K, Brigida K, Kamili S, Averhoff F, Nasrullah M. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1161-5. [PMID: 32853186 DOI: 10.15585/mmwr.mm6934a3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Li Q, Edwards TC, Ponzar NL, Tavis JE. A mid-throughput HBV replication inhibition assay capable of detecting ribonuclease H inhibitors. J Virol Methods 2021;292:114127. [PMID: 33766659 DOI: 10.1016/j.jviromet.2021.114127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
232 Liu X, Yuan L, Zhang L, Mu Y, Li X, Liu C, Lv P, Zhang Y, Cheng T, Yuan Q, Xia N, Chen X, Liu G. Bioinspired Artificial Nanodecoys for Hepatitis B Virus. Angew Chem Int Ed Engl 2018;57:12499-503. [PMID: 30088325 DOI: 10.1002/anie.201807212] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
233 Zhang KL, Chen XQ, Lv ZL, Tang Q, Shan QW. A simple noninvasive model to predict significant fibrosis in children with chronic hepatitis B. Medicine (Baltimore) 2021;100:e26462. [PMID: 34160448 DOI: 10.1097/MD.0000000000026462] [Reference Citation Analysis]
234 Ahmed FA, Bajaifar MS, Ahmed MA, Alalwan A, Sanai FA, Albeladi K, Aljumah AA, Sanai FM. Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients. Saudi J Gastroenterol 2019;25:286-92. [PMID: 31044750 DOI: 10.4103/sjg.SJG_80_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
235 Duong MC, Nguyen VTT, Otsu S, McLaws ML. Prevalence of hepatitis B and C virus infections in hemodialysis patients in Vietnam: A systematic review and meta-analysis. JGH Open. 2020;4:29-38. [PMID: 32055694 DOI: 10.1002/jgh3.12199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
236 Joshi SS, Davis RP, Ma MM, Tam E, Cooper CL, Ramji A, Kelly EM, Jayakumar S, Swain MG, Jenne CN, Coffin CS. Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD). NPJ Vaccines 2021;6:9. [PMID: 33431890 DOI: 10.1038/s41541-020-00266-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
237 Liu J, Fei Y, Zhou T, Ji H, Wu J, Gu X, Luo Y, Zhu J, Feng M, Wan P, Qiu B, Lu Y, Yang T, Deng P, Zhou C, Gong D, Deng J, Xue F, Xia Q. Bile Acids Impair Vaccine Response in Children With Biliary Atresia. Front Immunol 2021;12:642546. [PMID: 33936059 DOI: 10.3389/fimmu.2021.642546] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, Peppelenbosch MP, Liu J, Pan Q. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020;221:1677-1687. [PMID: 31778167 DOI: 10.1093/infdis/jiz633] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 39.0] [Reference Citation Analysis]
239 Li M, Zhao L, Zhou J, Sun Y, Wu X, Ou X, You H, Kong Y, Jia J. Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. Lancet Reg Health West Pac 2021;16:100249. [PMID: 34590058 DOI: 10.1016/j.lanwpc.2021.100249] [Reference Citation Analysis]
240 Chen R, Pei S, Chen Y, Tan L, Xue Y, Liu S, Huang Y, Fan X. Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report. Front Med (Lausanne) 2021;8:701061. [PMID: 34307428 DOI: 10.3389/fmed.2021.701061] [Reference Citation Analysis]
241 Wu YL, Kumar R, Wang MF, Singh M, Huang JF, Zhu YY, Lin S. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol 2021; 27(34): 5753-5763 [PMID: 34629799 DOI: 10.3748/wjg.v27.i34.5753] [Reference Citation Analysis]
242 Wang Y, Tang Z. A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. Onco Targets Ther 2018;11:8529-41. [PMID: 30555243 DOI: 10.2147/OTT.S188209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
243 Wang SJ, Chen ZM, Wei M, Liu JQ, Li ZL, Shi TS, Nian S, Fu R, Wu YT, Zhang YL, Wang YB, Zhang TY, Zhang J, Xiong JH, Tong SP, Ge SX, Yuan Q, Xia NS. Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection. Emerg Microbes Infect 2021;10:37-50. [PMID: 33296295 DOI: 10.1080/22221751.2020.1862631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Shimakawa Y, Vernoux L, Gabassi A, Mercier-Delarue S, Vincent JP, Simon F, Maylin S. Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS). J Viral Hepat 2021;28:837-43. [PMID: 33599049 DOI: 10.1111/jvh.13489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
245 Vaillant A. Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. Viruses 2021;13:745. [PMID: 33922828 DOI: 10.3390/v13050745] [Reference Citation Analysis]
246 Freeland C, Farrell S, Kumar P, Kamischke M, Jackson M, Bodor S, Block TM, Frasso R, Cohen C. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. BMC Public Health 2021;21:1004. [PMID: 34044808 DOI: 10.1186/s12889-021-11093-0] [Reference Citation Analysis]
247 Meng J, Xu H, Sui D, Jiang J, Li J, Gao Y, Niu J. A retrospective serological survey of hepatitis B virus infection in Northeast China. BMC Infect Dis 2019;19:440. [PMID: 31109300 DOI: 10.1186/s12879-019-4091-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
248 Guvenir M, Arikan A. Hepatitis B Virus: From Diagnosis to Treatment. Pol J Microbiol 2020;69:391-9. [PMID: 33574867 DOI: 10.33073/pjm-2020-044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
249 Cai Y, Yin W. The Multiple Functions of B Cells in Chronic HBV Infection. Front Immunol 2020;11:582292. [PMID: 33381113 DOI: 10.3389/fimmu.2020.582292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
250 Budzinska MA, Shackel NA, Urban S, Tu T. Cellular Genomic Sites of Hepatitis B Virus DNA Integration. Genes (Basel) 2018;9:E365. [PMID: 30037029 DOI: 10.3390/genes9070365] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
251 Zhang X, Dong P, Xu L, Tian Y, Sun H, Shi H, Duan Z, Chen L, Ren F. The different expression of caspase-1 in HBV-related liver disease and acts as a biomarker for acute-on-chronic liver failure. BMC Gastroenterol 2019;19:148. [PMID: 31429707 DOI: 10.1186/s12876-019-1064-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
252 Pu D, Yin L, Zhou Y, Li W, Huang L, Cai L, Zhou Q. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review. Medicine (Baltimore) 2020;99:e19013. [PMID: 32000444 DOI: 10.1097/MD.0000000000019013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 25.0] [Reference Citation Analysis]
253 Jing W, Liu J, Liu M. Eliminating mother-to-child transmission of HBV: progress and challenges in China. Front Med 2020;14:21-9. [PMID: 31974872 DOI: 10.1007/s11684-020-0744-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
254 Anugwom CM, Allaire M, Akbar SMF, Sultan A, Bollipo S, Mattos AZ, Debes JD. Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology. Hepatoma Res 2021;7:23. [PMID: 33884303 DOI: 10.20517/2394-5079.2021.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
255 Raad II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018; 10(9): 549-557 [PMID: 30310533 DOI: 10.4254/wjh.v10.i9.549] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
256 Abaalkhail FA, Al-Hamoudi WK, Khathlan A, Alghamdi S, Alghamdi M, Alqahtani SA, Sanai FM. SASLT practice guidelines for the management of Hepatitis B virus - An update. Saudi J Gastroenterol 2021;27:115-26. [PMID: 33976009 DOI: 10.4103/sjg.sjg_539_20] [Reference Citation Analysis]
257 Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular Mechanisms of Liver Fibrosis. Front Pharmacol 2021;12:671640. [PMID: 34025430 DOI: 10.3389/fphar.2021.671640] [Reference Citation Analysis]
258 Boldt ABW, Oliveira-Toré CF, Kretzschmar GC, Weinschutz Mendes H, Stinghen ST, Andrade FA, Bumiller-Bini V, Gonçalves LB, Braga ACM, Stahlke EVRS, Velavan TP, Thiel S, de Messias-Reason IJT. Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors. Front Immunol 2020;11:574457. [PMID: 33643280 DOI: 10.3389/fimmu.2020.574457] [Reference Citation Analysis]
259 Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis 2020;7:291-8. [PMID: 32884983 DOI: 10.1016/j.gendis.2019.12.014] [Reference Citation Analysis]
260 Si J, Yu C, Guo Y, Bian Z, Meng R, Yang L, Chen Y, Jin J, Liu J, Guo Z, Chen J, Chen Z, Lv J, Li L; China Kadoorie Biobank Collaborative Group. Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people. BMJ Open 2019;9:e027696. [PMID: 30967410 DOI: 10.1136/bmjopen-2018-027696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
261 Tsuruoka M, Inoue J, Onishi Y, Ninomiya M, Kakazu E, Iwata T, Sano A, Sato K, Harigae H, Masamune A. Hepatitis B Virus Reactivation with Discontinuation of Nucleoside Analogue in Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation. Case Rep Gastroenterol 2021;15:178-87. [PMID: 33708067 DOI: 10.1159/000512397] [Reference Citation Analysis]
262 Périères L, Marcellin F, Lo G, Protopopescu C, Ba EH, Coste M, Touré Kane C, Maradan G, Diallo A, Sokhna C, Boyer S, On Behalf Of The Anrs AmBASS Survey Study Group. Hepatitis B Vaccination in Senegalese Children: Coverage, Timeliness, and Sociodemographic Determinants of Non-Adherence to Immunisation Schedules (ANRS 12356 AmBASS Survey). Vaccines (Basel) 2021;9:510. [PMID: 34063390 DOI: 10.3390/vaccines9050510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Lu YX, He CZ, Wang YX, Ai ZS, Liang P, Yang CQ. Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study. Infect Dis Ther 2021;10:241-52. [PMID: 33111216 DOI: 10.1007/s40121-020-00355-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
264 Jiang XY, Huang B, Huang DP, Wei CS, Zhong WC, Peng DT, Huang FR, Tong GD. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World J Gastroenterol 2021; 27(11): 1101-1116 [PMID: 33776376 DOI: 10.3748/wjg.v27.i11.1101] [Reference Citation Analysis]
265 Zheng Y, Wu J, Ding C, Xu K, Yang S, Li L. Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study. Virol J 2020;17:132. [PMID: 32859216 DOI: 10.1186/s12985-020-01393-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
266 Chen X, Mao Q, Xie Y, Dou X, Xie Q, Sheng J, Gao Z, Zhou X, Liu Y, Zheng H, Zhang S, Li S, Zhu F, Xu Y, Zhang M, Hu Y, Chen X, Huang Y, Ren H, Jia J. A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a. J Clin Transl Hepatol 2019;7:249-57. [PMID: 31608217 DOI: 10.14218/JCTH.2019.00016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Asor R, Schlicksup CJ, Zhao Z, Zlotnick A, Raviv U. Rapidly Forming Early Intermediate Structures Dictate the Pathway of Capsid Assembly. J Am Chem Soc 2020;142:7868-82. [PMID: 32233479 DOI: 10.1021/jacs.0c01092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
268 Zhang YT, Liu J, Pan XB, Gao YD, Hu YF, Lin L, Cheng HJ, Chen GY. Successful treatment of infantile hepatitis B with lamivudine: A case report. World J Clin Cases 2021; 9(14): 3442-3448 [PMID: 34002156 DOI: 10.12998/wjcc.v9.i14.3442] [Reference Citation Analysis]
269 Lopez AL, Ylade M, Daag JV, Tandoc AO 3rd, Bonifacio J, Sylim PG, Sy AK, Centeno R, Roque V Jr, Ducusin MJ. Hepatitis B seroprevalence among 5 to 6 years old children in the Philippines born prior to routine hepatitis B vaccination at birth. Hum Vaccin Immunother 2018;14:2491-6. [PMID: 29852077 DOI: 10.1080/21645515.2018.1480278] [Reference Citation Analysis]
270 Matthews PC. FAIR data needed to liberate hepatitis B virus (HBV) from the catch-22 of neglect. J Glob Health 2019;9:010310. [PMID: 30992982 DOI: 10.7189/jogh.09-010310] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
271 Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, Li X, Ren T, Yang R, Feng F, Li BA, Zhao Q. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis 2018;9:743. [PMID: 29970890 DOI: 10.1038/s41419-018-0804-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 56] [Article Influence: 14.0] [Reference Citation Analysis]
272 Sahu T, Mehta A, Ratre YK, Jaiswal A, Vishvakarma NK, Bhaskar LVKS, Verma HK. Current understanding of the impact of COVID-19 on gastrointestinal disease: Challenges and openings. World J Gastroenterol 2021; 27(6): 449-469 [PMID: 33642821 DOI: 10.3748/wjg.v27.i6.449] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]